Summary.-Using a regrowth-delay assay, we investigated structure/activity relationships for the enhancement by electron-affinic agents of the anti-tumour effect of the nitrosourea CCNU against the KHT sarcoma in C3H mice. A series of neutral 2-nitroimidazoles similar in electron affinity but varying in octanol/water partition coefficient (PC) over 4 orders of magnitude (0.016->200, Misonidazole=0.43) were examined at a fixed dose of 2-5 mmol/kg. A parabolic (quadratic) dependence of activity on log PC was observed. Analogues more hydrophilic than misonidazole (MISO) were inactive as were those with very high PCs (>20). Those with PC 0.43-20 were usually more active than MISO, some considerably so. The fairly lipophilic 5-nitroimidazoles nimorazole and metronidazole (METRO) had similar activity to MISO, despite their reduced electron affinity. Two basic 2-nitroimidazoles more efficient as radiosensitizers in vitro likewise showed activity comparable to MISO. We also investigated several agents more electron-affinic than MISO, including some non-nitro compounds. Most were inactive at maximum tolerated doses, but nitrofurazone showed reasonable activity. Sensitizer dose-response curves were obtained for MISO, METRO and two of the most effective agents, benznidazole (go 07-1051) and Ro 07-1902. The two latter agents were both considerably more active than MISO at low doses (0-1-0.9 mmol/kg).
SEVERAL RECENT STUDIES have shown that, as well as sensitizing hypoxic cells to radiation, electron-affinic nitroimidazoles such as misonidazole (MISO) and metronidazole (METRO) can enhance the in-vivo anti-tumour activity of cytotoxic agents (reviewed by McNally, 1982; Brown, 1982) . This effect is seen particularly with nitrogen mustards and nitrosoureas, and in some cases there is evidence that enhancement of cytotoxicity can be greater in tumours than in doselimiting normal tissues.
To optimize combination strategies of this kind, structure/activity relationship studies are needed to identify the molecular features required by both the cytotoxic drug and the electron-affinic sensitizer. In a preceding paper we described the interactions between either MISO or METRO and a number of cytotoxics in the RIF-1 tumour (Twentyman & Workman, 1982 ). Here we report on the structure/activity relationships for the enhancement by a variety of electronaffinic agents of the anti-tumour effects of the nitrosourea CCNU against the KHT sarcoma in C3H mice. CCNU was chosen on the basis of previous studies which showed a considerable increase in (,3-diethylaminoethyl diphenylpropylacetate hydrochloride, or proadifen hydrochloride) was supplied by Smith Kline and French (Welwyn) and CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosurea) bythe Drug Synthesis and Chemistry Branch of the NCI and by Lundbeck. Basic structural formulae are shown in Fig. 1 . Other details of structure, oneelectron reduction potentials (El) and octanol/water partition coefficients (PC) are given in the Table. Mice and tumours.-C3H/He mice were obtained from OLAC and our own breeding colony. Both sexes were used, and were usually 12-16 weeks old and 20-30 g on entering experiments. They were allowed laboratory chow and water ad lib.
Procedures for handling the KHT fibrosarcoma are described elsewhere (Kallman et al., 1967; Twentyman et al., 1979) . Tumours were grown i.m. in the hind limb and treated in the size range 300-600 mg. The time taken for individual tumours to reach 4 x the initial group-mean volume was calculated and the median values for each treatment group obtained. Growth delay was calculated with respect to the control group. Groups contained 8-10 mice.
Drug administration.-In most experiments test compounds were injected 30 min before CCNU, but in some MISO was given immediately before. The three SR-compounds were injected i.v., all others i.p. Most were dissolved in Hanks' balanced salt solution (pH 7-4), and injected i.p. at 0 04 ml/g body weight. SKF 525A was given in 0-01-0O04 ml/g, Ro 31-0602 in 0-08 ml/g and METRO in 0-04-0-16 ml/g. Imidazole was dissolved in Hanks' and the pH corrected to 7-4 Cl (CH 2)2 N(NO)CONH (1) where x is the test compound, GD is growth delay, the MISO dose is 2-5 mmol/kg and CCNU dose 10 mg/kg. In practice, there was no significant growth delay for MISO alone or for most test compounds; thus these terms were usually omitted. Using Al values, compounds were ranked for chemosensitization effectiveness against MISO (Al = 1).
Multiple regression analysis was carried out using the GLIM computer program (Version 3).
Body temperature.-At the doses used in this study, certain test compounds reduced mouse body temperature. In some experiments normal body termperatures were maintained in an incubator or with a lamp. Temperatures were measured with a rectal thermister probe and an electrical thermometer.
RESULTS
Enhancement of CCNU response by MVIISO Fig. 2 shows typical data for the effect of MISO on the GD response of the KHT tumour to CCNU. The main effect is to remove the shoulder from the dose/ response curve. The degree of enhancement is about the same for 2f5 as for 5 mmol/kg, and is similar whether MISO is given 30 min or immediately before CCNU. This is in good agreement with the GD and cell-survival data of Siemann (1981, 1982) .
Enhancement of CCNU response by other agents
General.
-On the basis of the above experiments, a standard procedure was adopted for screening (see Methods). Compounds were given at 2-5 mmol/kg (or at MTD, if this was less) 30 min before 10 mg/kg CCNU. Except for CB 1954 and azathioprine, which gave barely significant but reproducible growth delays of about 1 day, none of the test compounds delayed growth when given alone.
The response to 10 and 20 mg/kg CCNU and 10 mg/kg CCNU plus 2 5 mmol/kg MISO were generally similar Table. The line is the best fit for the quadratic relationship (see equation (3)).
Points are means of activity indices in Table. to those seen in Fig. 2 (Table) .
MIultiple regression analysis wN-as used to analyse the data for the neutral 2-and 5-nitroimidazoles showing measurable enhancement at 2-5 mmol/kg (i.e. com- pounds 4-10, 15 and 16). The data were fitted to a structure/activity relationship of the form (Hansch, 1971 ):
log AI = b2 log PC + b3 (log PC)2 + K (2) where b2 and b3 are constants calculated from the regression, and the constant K was fixed to force the data through the MISO datum point. The mean AI was used for each compound, with a weighting equal to the product of Al and the square root of the number of estimations. The best fit (± s.e.) obtained was:
log AI= (0-472 +0*124) log PC-(0-567 + 0*184) log PC2 + 0.250 n=8, R2=0.71 ( 3) where n is the number of data sets analysed in the regression, and R2 the multiple-correlation coefficient, which shows that 71% of the variance in the data is explained by Equation (3). Omitting the quadratic term, the best fit obtainable was:
log Al = (0.228 + 04142) log PC + 0.0825 n=8, R2=0*25
Only 25% of the variance is explained by Equation (4), and the improvement by including the quadratic term is highly significant (0'01 <P <0-025, F distribution on 1, 5 d.f.).
To determine the effect of electron affinity, the term b1 (E 1) was added to the right-hand side of Equation (2).
There was only a slight improvement in explained variance (78%) and this was not significant (P > 0-25, F distribution on 1, 5 d.f.). Thus, the data are best described by the quadratic relationship given in Equation (3).
Others.-The 2-nitroimidazoles 13 and 14 have basic substituents which are ionized at physiological pH. Neither was more effective than MISO (Table) .
The remaining nitroheterocyclic compounds, comprising the highly electronaffinic nitrofurans nitrofurazone (19) and nitrofurantoin (20), the 5-substituted 4-nitroimidazolesNSC 38087 (17) and azathioprine (18), and the dinitrophenyl-azirdine CB 1954 (21) were toxic at 2-5 mmol/kg. At close to MTD nitrofurazone was reasonably active, but less than 2-5 mmol/kg MISO, whereas azathioprine was more active than MISO. The others had little or no activity.
Of the non-nitro electron-affinic agents. the two highly electron-affinic quinones, duroquinone (22) and menadione (23) were quite toxic, with little or no activity. The less electron-affinic anthraquinone sulphonate (24) was non-toxic at 2-5 mmol/kg and exhibited reasonable activity.
Two non-electron-affinic compounds were investigated. Imidazole (25) was ineffective at 2-5 mmol/kg and also at 5 mmol/kg (not shown). The hepatic microsomal-enzyme inhibitor SKF 525A (26) was active at 0-13 mmol/kg. Dose/response curves.-The effect of the dose of the electron-affinic agent on the response of the KHT tumour to 10 mg/kg CCNU was determined for MISO (5), METRO (15) and the two most effective agents Ro 07-1902 (7), and BENZO (9). Fig. 4 shows combined data from a series of independent experiments. In these studies METRO was rather less active than MISO, whereas the others were confirmed as more active, even at low doses. Although Ro 07-1902 (7) was the most active at high doses, BENZO (9) showed good activity at doses down to 0-05-0-1 mmol/kg. The dose/response curve for BENZO is rather flat from 0'1 to 4 mmol/kg.
Fffect of body temperature on response
High doses of MISO, METRO and other lipophilic nitroimidazoles cause mice to become torpid and hypothermic (Workman & . At 2-5 mmol/kg, MISO decreased body temperature by only 1-2°C and the hydrophilic analogues had no effect. Those more lipophilic than MISO produced a bigger decrease (up to 5-6°C) as did anthraquinone sulphonate (24). Ro 31-0602 (10) at 2*5 mmol/kg appeared to cause temporary paralysis, but this was not seen at lower doses. It seems unlikely that these effects make a major contribution to tumour response. Very high doses of METRO (e.g. 10 mmol/kg) reduced temperature by 10°C but the tumour response was about the same as with 2-5 mmol/kg MISO (Fig. 4) . Furthermore, by reducing the dose of the lipophilic analogues, good tumour responses were maintained (Fig. 4) without a marked temperature fall. In three experiments with the active lipophilic analogue Ro 07-1902 (7) tumour response to 10 mg/kg CCNU plus 2 5 mmol/kg Ro 07-1902 was determined in mice whose body temperatures either were allowed to fall to about 32°C or were maintained at 36-37°C in an incubator or with a lamp. There was no difference in tumour response.
DISCUSSION
These studies, along with several others (Siemann, 1981 (Siemann, , 1982 Hirst et al., 1982) demonstrate that the response of the KHT tumour to CCNU can be increased considerably by MISO.
Enhancement of in vivo tumour response to CCNU by 2-5-5 mmol/kg MISO has been demonstrated also with the RIF-1 sarcoma (Siemann, 1981 (Siemann, , 1982 Twentyman & Workman, 1982) , Lewis lung carcinoma (Stephens et al., 1981) , MT-1 mammary tumour (Siemann, 1982) , SCC VII/St carcinoma and EMT6/St/lu tumour (Hirst et al., 1982) . We are not aware of any experiments where these doses of MISO have failed to enhance response to CCNU. In addition, doses of 2-5-5 mmol/kg MISO enhanced tumour response to methyl-CCNU and BCNTU in most tumours evaluated (Clement et al., 1980; Stephens et al., 1981; Tannock, 1980b; Mulcahy et al., 1981; Clutterbuck et al., 1982) , and MISO also enhanced KHT tumour response to PCNU but not to chlorozotocin (Mulcahy, 1982) . Taken overall, chemosensitization with CCNU appears to be at least as good as that seen for other cytotoxics.
To find the best sensitizer-nitrosourea combinations, detailed structure/activity studies are required. The present paper gives data for 26 compounds, mostly electron-affinic, in combination with CCNU against the KHT tumour. By analogy with structure/activity relationships for radiosensitization (e.g. Adams et al., 1979; Anderson et al., 1981) we were particularly interested in the effects of lipophilicity and electron-affinity. For the neutral 2-and 5-nitroimidazoles, PC varied from 0-014-> 200. Of those more hydrophilic than MISO the 3 SR compounds (1-3) were completely inactive at 2-5 mmol/kg, and DEMIS (4) considerably less effective. Siemann (1982) observed similar results with SR-2508 (3), SR-2555 (2) and DEMIS at 5 mmol/kg. Some enhancement of RIF-1 tumour response was obtained with SR-2508, but only at high CCNU doses (> 20 mg/kg) and less than obtained with MISO. A similar lack of effect of SR-2508 was also seen by Hirst et al. (1982) .
We observed much greater activity with lipophilic nitroimidazoles. At 2-5 mmol/kg, several MISO analogues with PC 1-10 gave superior enhancement of CCNU response (Fig. 3) . Furthermore, Ro 07-1902 (7) and particularly BENZO (9) were active at much lower doses than MISO (Fig. 4) . The superior activity of BENZO has been confirmed recently by Siemann (personal communication) . Lipophilicity cannot be increased much further, however, before activity is lost, the overall dependence being parabolic (Fig. 3) .
It was not possible to examine the influence of electron affinity on enhancement of CCNU response in quite as much depth, because of the toxicity of the highly electron-affinic compounds. Nevertheless, enhancement data were obtained for compounds with El values from -486 to -203 mV, and are sufficient to demonstrate that electron affinity is less important than lipophilicity. For the neutral 2-and 5-nitroimidazoles, multiple regression analysis revealed no significant advantage in including an electron-affinity term into the quadratic expression for lipophilicity. Of the compounds more electron-affinic than MISO, only nitrofurazone (19) showed comparable enhancement of CCNU response at MTD (Table) . The other 5-nitrofuran, nitrofurantoin (20), was virtually inactive, as were the non-nitro compounds duroquinone (22) and menadione (23). The two quinones are very lipophilic, which may contribute to their lack of enhancement; however, the nitrofurans have PC values close to the optimal range for nitroimidazoles. Another non-nitro compound anthraquinone-2-sulphonate (24) has similar electron affinity to MISO, was less toxic than the more electronaffinic quinones, and showed reasonable enhancement at 2-5 mmol/kg, despite its hydrophilicity.
It is useful to compare our structure/ activity relationships for enhancement of CCNU response in vivo with those for radiosensitization. In vitro radiosensitization of hypoxic cells by neutral MISO analogues is largely dependent on electron affinity. Although some effect is seen at extreme PC values (Anderson et al., 1981; Brown et al., 1982) lipophilicity has relatively little influence. In vivo structure/ activity relationships are inevitably more complex, because of pharmacokinetic considerations, and this applies to both radiosensitization and chemosensitization. However, selected examples will demonstrate that the structural features required for the two effects are rather different. For example, Rauth et al. (1978) evaluated the 2-nitroimidazoles 4, 5, 6, 7 and 11 for in vivo radiosensitization, using the same tumour and mouse strain and similar timing to the present study. Ro 07-1902 (7) showed radiosensitization comparable to MISO, whereas it is considerably more active in enhancing the CCNU response. Both the hydrophilic DEMIS (4) and the lipophilic Ro 07-1127 (11) gave good radiosensitization, but have little or no ability to enhance the CCNU response. Pharmacokinetic considerations are clearly not responsible for the inactivity of the hydrophilic analogues DEMIS, SR-2508 and SR-2555 with CCNU, since these achieve plasma and tumour levels sufficient for radiosensitization comparable to MISO (Brown & Workman, 1980; Brown et al., 1981) . They may, however, contribute to the inactivity of the most lipophilic and the most electron-affinic analogues. Quantitative differences in the pharma-256 cokinetics of MISO between experimental animals and man are well established (Workman & Brown, 1981) and therefore caution should be exercised in extrapolating chemosensitization data directly to man. Pharmacokinetic studies are in progress with this series and some preliminary data have been reported (White et al., 1982) . It should be noted that the ability of the markedly hydrophilic anthraquinone-2-sulphonate (24) to enhance CCNU response may be due to free anthraquinone, since sulphonate groups are rapidly metabolized in mice (Zanelli & Kaelin, 1981) .
Recent in vitro studies have identified nitroimidazoles which radiosensitize hypoxic mammalian cells more efficiently than predicted from their electron affinities These include 2-nitroimidazoles with basic alkanolamine substituents partially protonated at physiological pH, and 5-substituted 4-nitroimidazoles (Adams et al., 1980a; Smithen et al., 1980) . We tested two alkanolamines, Ro 03-8799 (13) and RSU 1047 (14). At 2-5 mmol/kg both enhanced CCNU activity slightly less than MISO (Table) . Two 5-substituted 4-nitroimidazoles were examined, NSC 38087 (17) and azathioprine (18). The former was highly toxic and had little activity at MTD. In contrast, azathioprine at 1-4 mmol/kg was superior to 2-5 mmol/kg MISO (Table) . The dinitrophenylaziridine CB 1954 (21) is also a better-than-predicted radiosensitizer of hypoxic mammalian cells (Stratford et al., 1981 , but was rather toxic and gave no enhancement of CCNU response at MTD (Table) .
The mechanism of enhancement of nitrosourea response is unknown, but the main possibilities have been discussed (Siemann, 1981 (Siemann, , 1982 Mulcahy et al., 1981; Brown, 1982) . Enhancement of CCNU response was seen with EMT6 tumour spheroids after prolonged hypoxic pre-exposure to MISO in vitro, and was not due to inhibition of recovery from potentially lethal damage . In contrast, inhibition of clonogenic cell recovery was seen with the KHT tumour in vitro and carbamoylation of repair enzymes may be involved (Mulcahy, 1982) . Depletion of glutathione by MISO has been demonstrated (Brown, 1982) . Tannock (1980) (Klubes et al., 1979) . A possible mechanism which might be shared by SKF 525A and the nitroimidazoles of intermediate lipophilicity would be one operating through inhibition of re-routing of nitrosourea metabolism. This could accommodate (1) the absence of enhancement of CCNU response by hydrophilic analogues which are not metabolized, but cleared by the kidney (Workman & Brown, 1981) and thus are unlikely enzyme inhibitors, (2) the lack of enhancement of response to the hydrophilic nitrosourea chlorozotocin, also cleared by the kidney (Hoth et al., 1978) and (3) the lack of enhancement of CCNU response by the highly electron-257 affinic and other toxic analogues, because of inadequate concentrations for inhibition. The principal aim of this investigation was to identify for further attention compounds which might be superior chemosensitizers to MISO. The lipophilic analogues, particularly Ro and BENZO, clearly warrant more detailed evaluation. BENZO is ofparticular interest because the tumour enhancements reported here occur with doses much lower than with MISO, and plasma and tumour concentrations corresponding to active doses in mice can be maintained for several hours in dogs (White et al., 1982) . Daily doses of up to 0 03 mmol/kg BENZO have been used in the treatment of Chaga's disease in man (Coura et al., 1978 ) and the drug is eliminated with a half-life similar to MISO (Raaflub, 1980) . Preliminary studies in mice have demonstrated a therapeutic gain for combining BENZO with CCNU, and BENZO is now undergoing preliminary clinical evaluation as a chemosensitizer in this Unit.
In view of the therapeutic advantage which has been reported for the combination of MISO with CCNU (Siemann, 1981 (Siemann, , 1982 Twentyman & Workman, 1982a; Hirst et al., 1982) we are now evaluating the effect of combining BENZO or Ro with CCNU, and also with other cytotoxics for which they show improved enhancement over MISO, i.e. chlorambucil and cyclophosphamide (Twentyman & Workman, 1982b) and Melphalan (Sheldon & Batten, 1982; Clutterbuck & Miller, personal communication) . We are also optimizing the dose schedules, with emphasis on relevance to clinical pharmacokinetics.
